DoD’s BioDefense Therapeutics Announces Positive Results for Flu Treatment Drug

The successful completion of a Phase 2 double blind placebo-controlled clinical trial for the anti-influenza drug, T-705a (favipiravir), clears the way for Phase 3 clinical trials to begin in November. The investigational drug candidate is being developed by BioDefense Therapeutics (BD Tx)—a Joint Product Management office within the U.S. Department of Defense (DoD)—through a contract […]

MediVector Gets DoD Contract to Develop Flu Treatment

The Department of Defense’s (DOD) Joint Project Manager Transformational Medical Technologies (JPM-TMT) awarded a $138.5M contract to MediVector, Inc. to further develop Favipiravir (T-705), a broad-spectrum therapeutic against multiple influenza viruses, including the 2009 H1N1 pandemic virus and drug resistant influenza strains. The contract will help bolster the protection of the Joint Forces against naturally […]

JPM-TMT Announces Contract Award for Advanced Development of Broad-spectrum Influenza Drug

The Department of Defense’s (DOD) Joint Project Manager Transformational Medical Technologies (JPM-TMT) awarded a $138.5M contract to MediVector, Inc. to further develop Favipiravir (T-705), a broad–spectrum therapeutic against multiple influenza viruses, including the 2009 H1N1 pandemic virus and drug resistant influenza strains. The contract will help bolster the protection of the Joint Forces against naturally […]